Adjuvant Therapy for Esophageal Squamous Cell Carcinoma

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Adjuvant therapy for resected esophageal squamous cell carcinoma (ESCC) is underutilized compared to neoadjuvant approaches.
• Despite lower utilization, adjuvant therapy significantly impacts survival outcomes in ESCC patients.
• Evidence supporting adjuvant treatment warrants further review and clinical consideration.

Purpose of the Study:

• To review the current evidence for adjuvant therapy in resected ESCC.
• To explore future directions in adjuvant treatment for ESCC.
• To highlight the potential role of immunotherapy in the adjuvant setting for ESCC.

Main Methods:

• Literature review of clinical trials and observational studies.
• Analysis of survival data related to adjuvant therapy in ESCC.
• Synthesis of evidence on emerging therapeutic strategies, including immunotherapy.

Main Results:

• Adjuvant therapy demonstrates a survival benefit for patients with resected ESCC.
• Current clinical practice favors neoadjuvant over adjuvant therapy, despite evidence.
• Immunotherapy shows promise as a future adjuvant treatment modality for ESCC.

Conclusions:

• Adjuvant therapy is a vital, albeit underused, strategy for improving survival in resected ESCC.
• Further research and clinical adoption of adjuvant therapy are recommended.
• Immunotherapy represents a promising frontier for enhancing adjuvant treatment efficacy in ESCC.